627 related articles for article (PubMed ID: 8517647)
1. Antitumor activity of idarubicin, a derivative of daunorubicin, against drug sensitive and resistant P388 leukemia.
Tsuruo T; Oh-Hara T; Sudo Y; Naito M
Anticancer Res; 1993; 13(2):357-61. PubMed ID: 8517647
[TBL] [Abstract][Full Text] [Related]
2. [Antitumor effects of Behenoyl-ara-C (BH-AC) in combination with Idarubicin (IDA) in P 388 leukemic cell bearing mice].
Watanabe A; Kuriyama H; Kiyota T
Gan To Kagaku Ryoho; 1996 Feb; 23(3):291-6. PubMed ID: 8712821
[TBL] [Abstract][Full Text] [Related]
3. The combination regimen of idarubicin and taxotere is effective against human drug-resistant leukemic cell lines.
Majlessipour F; Avramis IA; Kwock R; Weinberg KI; Avrami VI
Anticancer Res; 2002; 22(3):1361-8. PubMed ID: 12168812
[TBL] [Abstract][Full Text] [Related]
4. [The effect of finoptin on doxorubicin accumulation in leukemia P-388 cells with induced resistance to the combination of finoptin and doxorubicin].
Moroz LV; Donenko FV; Borovkova NB; Sitdikova SM; Kabieva AO
Biull Eksp Biol Med; 1990 Mar; 109(3):290-2. PubMed ID: 2364157
[TBL] [Abstract][Full Text] [Related]
5. High-dose idarubicin in combination with Ara-C in patients with relapsed or refractory acute lymphoblastic leukemia: a pharmacokinetic and clinical study.
Tedeschi A; Montillo M; Strocchi E; Cafro AM; Tresoldi E; Intropido L; Nichelatti M; Marbello L; Baratè C; Camaggi CM; Morra E
Cancer Chemother Pharmacol; 2007 May; 59(6):771-9. PubMed ID: 17256136
[TBL] [Abstract][Full Text] [Related]
6. [The cross resistance to cytostatics of leukemia P388 cells with induced resistance to doxorubicin].
Donenko FV; Sitdikova SM; Kabieva AO
Biull Eksp Biol Med; 1993 Sep; 116(9):309-11. PubMed ID: 8118011
[TBL] [Abstract][Full Text] [Related]
7. Characteristics of P388/VMDRC.04, a simple, sensitive model for studying P-glycoprotein antagonists.
Yang JM; Goldenberg S; Gottesman MM; Hait WN
Cancer Res; 1994 Feb; 54(3):730-7. PubMed ID: 7905786
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapy with [SP-4-3-(R)]-[1,1-cyclobutanedicarboxylato(2-)](2- methyl-1,4-butanediamine-N,N')platinum (CI-973, NK121) in combination with standard agents against murine tumors in vivo.
Elliott WL; Roberts BJ; Howard CT; Leopold WR
Cancer Res; 1994 Aug; 54(16):4412-8. PubMed ID: 8044790
[TBL] [Abstract][Full Text] [Related]
9. Potentiation of antitumor activity of pirarubicin by chlorpromazine in mice bearing doxorubicin-resistant P388 leukemia.
Shibata H; Maekawa I; Furusawa S; Kawauchi H; Takayanagi Y; Sasaki K
Res Commun Chem Pathol Pharmacol; 1990 Dec; 70(3):359-62. PubMed ID: 2093213
[TBL] [Abstract][Full Text] [Related]
10. Combination effects of Ara-C and 5-fluorodeoxyuridine against leukemia cells in vitro and in mice.
Rauko P; Bauer W; Horvath Z; Höchtl T; Saiko P; Karl D; Schott H; Fritzer-Szekeres M; Novotny L; Szekeres T
Anticancer Res; 2003; 23(5A):3841-6. PubMed ID: 14666686
[TBL] [Abstract][Full Text] [Related]
11. Cross-resistance of menogaril and mitoxantrone in a subline of P388 leukemia resistant to doxorubicin.
Chandrasekaran B; Dimling J; Capizzi RL
Cancer Treat Rep; 1987 Feb; 71(2):195-6. PubMed ID: 2948640
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of apoptosis induced in vitro by cladribine (2-CdA) combined with anthracyclines in lymphocytes from patients with B-cell chronic lymphocytic leukemia.
Szmigielska-Kaplon A; Smolewski P; Najder M; Robak T
Ann Hematol; 2002 Sep; 81(9):508-13. PubMed ID: 12373351
[TBL] [Abstract][Full Text] [Related]
13. Overcoming drug resistance in cancer cells with synthetic isoprenoids.
Yamaguchi T; Nakagawa M; Shiraishi N; Yoshida T; Kiyosue T; Arita M; Akiyama S; Kuwano M
J Natl Cancer Inst; 1986 May; 76(5):947-53. PubMed ID: 3457980
[TBL] [Abstract][Full Text] [Related]
14. A phase II comparative study of idarubicin plus cytarabine versus daunorubicin plus cytarabine in adult acute myeloid leukemia.
Masaoka T; Ogawa M; Yamada K; Kimura K; Ohashi Y
Semin Hematol; 1996 Oct; 33(4 Suppl 3):12-7. PubMed ID: 8916311
[TBL] [Abstract][Full Text] [Related]
15. Activity of SC33428, a novel bishydrazone-bridged derivative of 4-demethoxydaunorubicin, against experimental tumors in mice.
Dawson KM
Cancer Res; 1983 Jun; 43(6):2880-3. PubMed ID: 6573953
[TBL] [Abstract][Full Text] [Related]
16. [Synergism of sobuzoxane in combination with doxorubicin against leukemia P388 in mice].
Dai ZQ; Xu JY; Yuan XJ; Cai JC
Zhongguo Yao Li Xue Bao; 1996 Jan; 17(1):69-71. PubMed ID: 8737460
[TBL] [Abstract][Full Text] [Related]
17. Increased myelotoxicity of idarubicin: is there a pharmacological basis? Results of a pharmacokinetic and an in vitro cytotoxicity study.
Kroschinsky F; Schleyer E; Renner U; Schimming C; Schimmelpfennig C; Bornhäuser M; Illmer T; Trümper L; Ehninger G; Schaich M
Cancer Chemother Pharmacol; 2004 Jan; 53(1):61-7. PubMed ID: 12955471
[TBL] [Abstract][Full Text] [Related]
18. Idarubicin and idarubicinol are less affected by topoisomerase II-related multidrug resistance than is daunorubicin.
Fukushima T; Inoue H; Takemura H; Kishi S; Yamauchi T; Inai K; Nakayama T; Imamura S; Urasaki Y; Nakamura T; Ueda T
Leuk Res; 1998 Jul; 22(7):625-9. PubMed ID: 9680113
[TBL] [Abstract][Full Text] [Related]
19. Effects of Dex-Verapamil on Doxorubicin cytotoxicity in P388 murine leukemia cells.
Noviello E; Allievi E; Russo P; Parodi S
Anticancer Drug Des; 1997 Jun; 12(4):261-76. PubMed ID: 9199659
[TBL] [Abstract][Full Text] [Related]
20. Effects of 1-methyl-3-propyl-7-butylxanthine (MPBX) on idarubicin-induced antitumor activity and bone marrow suppression.
Sadzuka Y; Egawa Y; Sugiyama T; Sawanishi H; Miyamoto K; Sonobe T
Jpn J Cancer Res; 2000 Jun; 91(6):651-7. PubMed ID: 10874219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
